Literature DB >> 7734299

Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.

T Jørgensen1, K Yogesan, F Skjørten, A Berner, K J Tveter, H E Danielsen.   

Abstract

The present study compares the prognostic potential of tumour grade and DNA ploidy status in patients with advanced-stage prostatic cancer. Two outcome groups were selected on the basis of time to progression and survival after orchiectomy. A poor-outcome group consisted of 32 therapy-resistant patients who experienced disease progression during the first year after orchiectomy and subsequently death due to prostatic cancer during the following year. A good-outcome group consisted of 27 therapy-responsive patients who showed disease regression and no signs of progression during a 3 year follow-up. The primary tumours were graded twice according to WHO and Gleason classification systems by two pathologists. Final agreement between the pathologists was obtained after a consensus meeting. The analysis revealed no prognostic importance of the two histological classification systems (P = 0.62 and P = 0.70) and disclosed weak inter- and intra-observer reproducibility (kappa < 0.70). DNA ploidy analyses were performed by image cytometry on formalin-fixed, paraffin-embedded samples of the primary tumours. Overall, 48% of the tumours were diploid, 20% tetraploid and 32% anueploid. DNA ploidy status did not discriminate between the two outcome groups (P = 0.46). Histological grade and DNA ploidy showed no prognostic importance in patients with prostatic cancer and skeletal metastases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734299      PMCID: PMC2033801          DOI: 10.1038/bjc.1995.203

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Problems of grading carcinoma of prostate.

Authors:  F K Mostofi
Journal:  Semin Oncol       Date:  1976-06       Impact factor: 4.929

Review 2.  Proceedings: The natural history of prostatic cancer.

Authors:  W F Whitmore
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

4.  Correlation between ploidy and prognosis in prostatic carcinoma.

Authors:  A S Tavares; J Costa; J C Maia
Journal:  J Urol       Date:  1973-04       Impact factor: 7.450

Review 5.  New prognostic factors in prostatic carcinoma.

Authors:  T Visakorpi; O P Kallioniemi; T Koivula; J Isola
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 7.  Spread of prostatic cancer to bone.

Authors:  S C Jacobs
Journal:  Urology       Date:  1983-04       Impact factor: 2.649

8.  Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant therapy.

Authors:  P H Lange; P Narayan
Journal:  Urology       Date:  1983-02       Impact factor: 2.649

9.  Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.

Authors:  T Jørgensen; K J Tveter; L H Jørgensen
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

10.  Prognostic significance of nuclear DNA levels in prostatic carcinoma.

Authors:  A Zetterberg; P L Esposti
Journal:  Scand J Urol Nephrol Suppl       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.